Bevacizumab and Neovascular Age Related Macular Degeneration: Pathogenesis and Treatment

REFERENCES

• Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640–1642.
   PubMedGoogle Scholar
• Zarbin MA. Age-related macular degeneration: Review of pathogenesis. Eur J Ophthalmol. 1998 Oct-Dec; 8(4):199–206.
   PubMedGoogle Scholar
• Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2000 Sep-Oct; 45(2):115–34.
   PubMedGoogle Scholar
• Grossniklaus HE, Green WR. Histopathologic and ultrastructural findings of surgically excised choroidal neovascularization. Submacular surgery trials research group. Arch Opthalmol. 1998;116:745–749.
   PubMedGoogle Scholar
• Hermans P, Lommatzsch A, Bornfeld N, Pauleikhoff D. Angiographic-histological correlation of late exudative age-related macular degeneration. Ophthalmologe. 2003;100:378–383.
   PubMedGoogle Scholar
• Kliffen M, van der Schaft TL, Mooy CM, de Jong PTVM. Morphologic changes in age-related maculopathy. Microsc ResTech. 1997;36:106–122.
   PubMed Web of Science ®Google Scholar
• Lopez PF, Grossniklaus HE, Lambert HM, Aaberg TM, Capone A Jr, Sternberg P Jr, L’Hernault N. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Opthalmol. 1991; 112:647–656.
   PubMed Web of Science ®Google Scholar
• Lommatzsch A, Hermans P, Müller KD, Bornfeld N, Bird AC, Pauleikhoff D. Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits. Graefes Arch Clin Exp Ophthalmol. 2008 Jun; 246(6):803–10.
   PubMedGoogle Scholar
• Fajnkuchen F, Cohen SY. Update on the genetics of age-related macular degeneration. J Fr Ophtalmol. 2008 Jun; 31(6):630–7.
   PubMedGoogle Scholar
• Grindle CF, Marshall J. Ageing changes in Bruch’s membrane and their functional implications. Trans Ophthalmol Soc UK.1978;98:172–175.
   PubMedGoogle Scholar
• Diego G. Espinosa-Heidmann, Ivan J. Suner, Eleut P. Hernandez, Dagoberto Monroy, Karl G. Csaky, and Scott W. Cousins. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Investigative Ophthalmology & Visual Science. 2003;44(8):3586–3592.
   PubMedGoogle Scholar
• Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Investigative Ophthalmology & Visual Science. 2003;44:3578–3585.
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Ling JX, Wallace TM, Dithmar S, Lawson DH, Cohen C, Elner VM, Elner SG, Sternberg P JR. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002 Apr 21; 8:119–26.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999 Jul; 77(7):527–43.
   PubMedGoogle Scholar
• Keyt BA, Berleau LT, Nguyen HV, Chen H, Heinsohn H, Vandlen R, Ferrara N. The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem. 1996 Mar 29;271(13):7788–95.
   PubMedGoogle Scholar
• de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992 Feb 21; 255(5047):989–91.
   PubMedGoogle Scholar
• Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D, Böhlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun. 1992 Sep 30; 187(3):1579–86.
   PubMedGoogle Scholar
• Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem. 1994 Oct 14; 269(41):25646–54.
   PubMedGoogle Scholar
• Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989 Dec 8; 246(4935):1306–9.
   PubMed Web of Science ®Google Scholar
• Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983 Feb 25; 219(4587):983–5.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest. 1987 Dec; 57(6):673–86.
   PubMedGoogle Scholar
• Hoffmann S, He S, Ehren M, et al. MMP-2 and MMP-9 secretion by RPE is stimulated by angiogenic molecules found in choroidal neovascular membranes. Retina. 2006;26:454–61.
   PubMed Web of Science ®Google Scholar
• Tatar O, Adam A, Shinoda K, et al. Matrix metalloproteinases in human choroidal neovascular membranes excised following verteporfin photodynamic therapy. Br J Ophthalmol. 2007;91:1183–9.
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy Five-year results from randomized clinical trials Macular Photocoagulation Study Group. Archives of Ophthalmology. 1991;109(8):1109–14.
   PubMedGoogle Scholar
• Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials—TAP report. Arch Ophthalmol. 1999; 117:1329–45.
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age related macular degeneration: Two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541–60.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004; 351(27):2805–2816.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine 2006;355(14):1419–31.
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim R, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New England Journal of Medicine. 2006; 355(14):1432–44.
   PubMedGoogle Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566–583.
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997 Oct 15;57(20):4593–9.
   PubMed Web of Science ®Google Scholar
• Muller YA, Chen Y, Christinger HW, Li B, Cunningham BC, Lowman HB, de Vos AM. VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 A resolution and mutational analysis of the interface. Structure. 1998 Sep 15;6(9):1153–67.
   PubMedGoogle Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035–1047.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab(avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:336–339.
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007 Jan;245(1):68–73.
   PubMedGoogle Scholar
• Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006 Apr;26(4):383–90.
   PubMedGoogle Scholar
• Aggio FB, Farah ME, Silva WC, Melo GB. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments. Graefes Arch Clin Exp Ophthalmol. 2007 Feb;245(2):215–20.
   PubMedGoogle Scholar
• Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006 Jul;142(1):1–9.
   PubMedGoogle Scholar
• Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008 Jan;246(1):81–7.
   PubMedGoogle Scholar
• Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 2006;26:257–261.
   PubMed Web of Science ®Google Scholar
• Jeganathan VS, Verma N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr Opin Ophthalmol. 2009 May;20(3):223–5.
   PubMedGoogle Scholar
• Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology. 2008 Oct;115(10):1837–46.
   PubMedGoogle Scholar
• Wu L, Arevalo JF, Maia M, Berrocal MH, Sanchez J, Evans T, for the Pan-American Collaborative Retina Study Group (PACORES). Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: Results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol 2009;53:125–130.
   PubMed Web of Science ®Google Scholar
• Carneiro AM, Falcão MS, Brandão EM, Falcão-Reis FM. Intravitreal bevacizumab for neovascular age-related macular degeneration with or without prior treatment with photodynamic therapy: One-year results. Retina. 2010 Jan;30(1):85–92.
   PubMedGoogle Scholar
• Mekjavic PJ, Kraut A, Urbancic M, Lenassi E, Hawlina M. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmol. 23Oct 2009, DOI 10.1111/j.1755-3768.2009.01740.x.
   PubMedGoogle Scholar
• Costagliola C, Romano M, Corte MD, Perrotta R, Menzione M, Rinaldi M, Semeraro F, Parmeggiani F. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: A 12-month follow-up study. Retina. 2009 Oct;29(9):1227–34.
   PubMedGoogle Scholar
• Leydolt C, Michels S, Prager F, Garhoefer G, Georgopoulos M, Polak K, Schmidt-Erfurth U. Effect of intravitreal bevacizumab (Avastin(R)) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. Acta Ophthalmol. 2010 Aug; 88(5):594–600.
   PubMedGoogle Scholar
• Fong KC, Kirkpatrick N, Mohamed Q, Johnston RL. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration using a variable frequency regimen in eyes with no previous treatment. Clin Experiment Ophthalmol. 2008 Nov;36(8):748–55.
   PubMedGoogle Scholar
• Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008 Feb;145(2):249–256.
   PubMedGoogle Scholar
• Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: Results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Retina. 2008 Nov-Dec;28(10):1387–94.
   PubMedGoogle Scholar
• Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2009 Oct 29. 2010 Mar; 51(3):1606–8.
   PubMedGoogle Scholar
• Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007 May;114(5):855–9.
   PubMedGoogle Scholar
• Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2009 May;53(3):243–8.
   PubMedGoogle Scholar
• Shah AR, Del Priore LV. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements. Br J Ophthalmol. 2009 Aug;93(8):1027–32.
   PubMedGoogle Scholar
• Gordon-Angelozzi M, Velez-Montoya R, Fromow-Guerra J, García-Aguirre G, Guerrero-Naranjo JL, Quiroz-Mercado H, Morales-Cantón V. Bevacizumab local complications. Ophthalmology. 2009 Nov; 116(11): 2264.e1-3.
   PubMedGoogle Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: Using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006 Nov; 90(11):1344–9.
   PubMedGoogle Scholar
• Sheybani A, Kymes S, Schlief S, Apte R. Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab. Retina. 2009 Nov-Dec;29(10):1404–8.
   PubMedGoogle Scholar
• Lee K, Yang H, Lim H, Lew HM. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina. 2009 Nov-Dec;29(10):1409–17.
   PubMedGoogle Scholar
• Kahook MY, Kimura AE, Wong LJ, Ammar DA, Maycotte MA, Mandava N. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging. 2009 May-Jun;40(3):293–5.
   PubMedGoogle Scholar
• Lima LH, Zweifel SA, Engelbert M, Sorenson JA, Slakter JS, Cooney MJ, Klancnik JM, Yannuzzi LA, Freund KB. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy. Retina. 2009 Oct;29(9):1213–7.
   PubMedGoogle Scholar
• Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina. 2009 Jun;29(6):723–31.
   PubMedGoogle Scholar
• Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer. 2009 May;45(7):1117–28.
   PubMedGoogle Scholar
• Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, Kent D. Expression of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular membranes. Graefes Arch Clin Exp Ophthalmol. 2009 Oct;247(10):1361–7.
   PubMedGoogle Scholar
• Guerin E, Sheridan C, Assheton D, Kent D, Wong D, Grant M, Hiscott P. SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation. Microvasc Res. 2008 Apr;75(3):302–7.
   PubMedGoogle Scholar
• Bhutto IA, McLeod DS, Merges C, Hasegawa T, Lutty GA. Localisation of SDF-1 and its receptor CXCR4 in retina and choroid of aged human eyes and in eyes with age related macular degeneration. Br J Ophthalmol. 2006 Jul;90(7):906–10.
   PubMedGoogle Scholar
• Takahashi H, Yanagi Y, Tamaki Y, Muranaka K, Usui T, Sata M. Contribution of bone-marrow-derived cells to choroidal neovascularization. Biochem Biophys Res Commun. 2004 Jul 23;320(2):372–5.
   PubMedGoogle Scholar
• Stahl A, Paschek L, Martin G, Feltgen N, Hansen LL, Agostini HT. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol. 2009 Jun;247(6):767–73.
   PubMedGoogle Scholar
• Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol. 2008;126:782–790.
   PubMed Web of Science ®Google Scholar
• Abdollahi A, Klatky L, Huber PE. Endostatin: The logic of antiangiogenic therapy. Drug Resist Updat. 2005;(8):59–74.
   PubMedGoogle Scholar
• Forooghian F, Chew EY, Meyerle CB, Cukras C, Wong WT. Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol. 2009 Nov 7.
   Google Scholar
• Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR. Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2008 Jul; 49(7):3115–20.
   PubMedGoogle Scholar
• Mojana F, Cheng L, Bartsch DU, Silva GA, Kozak I, Nigam N, Freeman WR. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008 Aug;146(2):218–227.
   PubMedGoogle Scholar
• Arias L, Caminal JM, Casas L, Masuet C, Badia MB, Rubio M, Pujol O, Arruga J. A study comparing two protocols of treatment with intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Br J Ophthalmol. 2008 Dec;92(12):1636–41.
   PubMedGoogle Scholar
• Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). http://www.med.upenn.edu/cpob/studies/CATT.shtml.
   Google Scholar
• Bremen-Mitte K. Prevention of vision loss in patients with age-related macular degeneration (amd) by intravitreal injection of bevacizumab and ranibizumab (VIBERA). http://www.clinicaltrial.gov/ct2/show/results/NCT00559715.
   Google Scholar
• Manta Study. Avastin versus Lucentis in age related macular degeneration (MANTA). http://www.clinicaltrial.gov/ct2/show/NCT00710229.
   Google Scholar
• Lapostolle S. Avastin/Lucentis Update 25: Comparative studies proliferate− France joins the fray. http://www.wellsphere.com/general-medicine-article/avastin-lucentis-update-25-comparative-studies-proliferate-france-joins-the-fray/801389.
   Google Scholar
• Khorram D. Head-to-head Lucentis vs. Avastin Trials. http://theretinablog.com/2009/10/25/head-to-head-lucentis-vs-avastin-trials.
   Google Scholar
• Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008 Dec;115(12):2199–205.
   PubMedGoogle Scholar
• Shima C, Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Tano Y. One-year results of combined photodynamic therapy and intravitreal bevacizumab injection for retinal pigment epithelial detachment secondary to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2009 Jul;247(7):899–906.
   PubMedGoogle Scholar
• Kaiser PK, Registry of Visudyne AMD Therapy Writing Committee, Boyer DS, Garcia R, Hao Y, Hughes MS, Jabbour NM, Kaiser PK, Mieler W, Slakter JS, Samuel M, Tolentino MJ, Roth D, Sheidow T, Strong HA. Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2009 Apr;116(4):747–55.
   PubMedGoogle Scholar
• Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007 Feb; 27(2):133–40.
   PubMedGoogle Scholar
• Costagliola C, Romano MR, Rinaldi M, Dell’omo R, Chiosi F, Menzione M, Semeraro F. Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age related macular degeneration. Br J Ophthalmol. 2010 Feb;94(2):180–4.
   PubMedGoogle Scholar
• Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina. 2009 May;29(5):573–8.
   PubMedGoogle Scholar